CC-11050
Sponsors
Amgen, The Aurum Institute NPC, The Leprosy Mission Nepal
Conditions
Cutaneous Lupus ErythematosusErythema Nodosum LeprosumHealthy VolunteersLeprosyTuberculosis
Phase 1
Phase 2
To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus
CompletedNCT01300208
Start: 2010-10-01End: 2013-03-01Updated: 2020-06-23
TB Host Directed Therapy
NCT02968927
Start: 2016-11-30End: 2020-12-31Updated: 2019-01-10
CC-11050 Trial in Nepalese Patients With Erythema Nodosum Leprosum
NCT03807362
Start: 2018-01-07End: 2024-12-31Target: 50Updated: 2020-07-07